The short answer
You can start a peptide clinic in 2026, and you cannot yet prescribe most of the peptides people are searching for. Both halves are true. On April 15, 2026, FDA removed twelve peptides from Category 2 of its 503A bulk-substances list (BPC-157, TB-500, KPV, MOTs-c, Semax, Epitalon, DSIP, LL-37, DiHexa, PEG-MGF, Melanotan II and injectable GHK-Cu), effective April 22 under docket FDA-2025-N-6895. On July 23 and 24 its Pharmacy Compounding Advisory Committee reviewed seven of them for the 503A bulks list. Press reported favorable votes on most; FDA has not published an updated list, and until it does, compounding pharmacies have no basis to prepare those peptides and prescribers have no basis to order them. Category 2 removal means "no longer flagged as a significant safety risk." It does not mean approved, and it does not mean compoundable.
What a clinic can offer today is the set of peptides that are FDA-approved drugs or are compounded under existing rules: the GLP-1s themselves (semaglutide and tirzepatide are peptides, and branded supply is unlimited), sermorelin, NAD+ (not a peptide, but sold alongside them), PT-141 as the approved drug Vyleesi or compounded where a pharmacy will, and a handful of others your pharmacy partner will list. The clinic that launches on those, with labs, protocols and a membership, is positioned to add BPC-157 the week the list changes. The clinic that launches on BPC-157 now is a warning letter with a website.
The legal map, September 2026
| Peptide | Status | Can a telehealth clinic offer it? |
|---|---|---|
| Semaglutide, tirzepatide (branded) | FDA-approved; manufacturer cash channels | Yes; the base of most clinics |
| Sermorelin | Widely compounded; listed in the Turbopills treatments directory | Yes, through a pharmacy that compounds it |
| NAD+ (injection, nasal) | Compounded; listed in the directory | Yes, through a compounding pharmacy |
| PT-141 (bremelanotide) | FDA-approved as Vyleesi; compounded versions common | Yes as the approved drug; compounded depends on the pharmacy |
| Tesamorelin | FDA-approved (Egrifta) for a narrow indication | Yes, on label; off-label prescribing is a clinical judgment |
| BPC-157, TB-500, KPV, MOTs-c | Off Category 2 since April 22; PCAC reviewed July 23 | Not until FDA publishes an updated 503A bulks list |
| Semax, Epitalon, DSIP (emideltide) | Off Category 2; PCAC reviewed July 24 | Not until the list updates |
| LL-37, DiHexa, PEG-MGF, Melanotan II, GHK-Cu (injectable) | Off Category 2; not on the July agenda | Not until nominated, reviewed and listed |
| Retatrutide, CagriSema | Investigational; Lilly files retatrutide in Q1 2027, Novo expects a CagriSema decision in Q4 2026 | No; see the CagriSema readiness post |
Two sources to bookmark: FDA's meeting page for the July 23-24 committee lists exactly which substances were reviewed and for which list, and our roadmap after the votes tracks the next steps. When the list changes, the first thing to check is whether a substance landed on the 503A list, the 503B list, or both, because that decides whether a patient-specific pharmacy or an outsourcing facility can supply it.
Tissue and Gut Recovery
The anchor group of a recovery-focused telehealth program. Most often paired together in clinical protocols.
Most discussed peptide in the recovery category. Studied for soft tissue, joint, ligament, and GI mucosa support.
Most often paired with BPC-157. Positioned around wound healing, soft tissue flexibility, and post-injury recovery.
Anti-inflammatory peptide, with patient interest concentrated around gut health and certain skin conditions.
Why "research use only" is a trap
The peptide business most YouTube guides describe ("How to Start a Peptide Business in 2026", 18,000 views in April) is a research-use-only e-commerce store: vials labeled not for human use, sold to people who inject them. That business is ending. Peptide Sciences, one of the largest RUO sellers, shut down in March 2026; payment processors have been dropping the category, which is why a subreddit for peptide payment processing appeared the same month; and a September 21 Reddit post summarized the enforcement view in its title: "'Research use only' isn't protecting RUO peptide sellers. The FDA and DOJ are treating it as evidence." A clinic is the legal version of that demand, and the demand is large: Leerink estimated a $2.2 billion telehealth peptide market by 2027 in a note reported by Time on July 23, with Hims positioned to take a fifth of it. The clinic model has to be a clinic, though: a licensed prescriber, a documented evaluation, a pharmacy dispensing on a valid prescription, and nothing sold that the pharmacy cannot lawfully compound.
Physicians are watching with open hostility, which matters for a brand's credibility. The most upvoted reply when a plastic-surgery PA asked r/physicianassistant in April 2026 how a spa could offer BPC-157: "They are banned by the FDA, so no. That could be changing in the near future though." On r/medicine in May, a thread on FDA's peptide proposals ran to "FDA is becoming a joke." Barbell Medicine's August 7 episode was titled "The FDA Voted for 6 Peptides. Its Own Scientists Said No." A clinic that overstates evidence will be quoted by those people.
The clinic model that works now
The programs actually running in 2026 combine three things the RUO store never had. Labs first: a baseline panel, then the protocol, then follow-up labs; Hims bundles labs for free and reports 120-plus biomarkers through Quest. A protocol with a named clinical rationale per peptide and a stated stop rule. And a membership, typically $150 to $300 a month, that covers review, dosing changes and messaging, with the compounded product billed at the pharmacy's price. The membership-model longevity clinic post lays out the full stack, and the longevity stack post shows how peptides sit beside GLP-1s, NAD+ and hormones in one program.
Ownership follows the usual rule: a non-physician cannot own a corporation that sells prescription therapies to consumers in corporate-practice-of-medicine states, as a June 2026 Holt Law analysis of peptide clinics put it, so the structure is a physician-owned professional entity plus a management company, explained in the MSO and friendly-PC post.
The launch stack
| Layer | What it has to do for peptides specifically |
|---|---|
| Intake | Screen contraindications and state eligibility; capture goals and labs status; branch by protocol (recovery, metabolic, sleep, sexual health) |
| Labs | Order a baseline panel, ingest results, gate the prescription on them |
| Provider routing | Route to a licensed provider in the patient's state who works from the clinic's protocols; asynchronous where the state allows |
| Pharmacy | Route to a 503A pharmacy that compounds the specific peptide, with potency testing and cold chain; keep a second pharmacy configured |
| Billing | Membership captured on approval; product billed separately and transparently |
| Portal | Dosing schedules, reconstitution instructions, refill requests, side-effect reporting, follow-up lab reminders |
Turbopills ships that stack as one configured system under the clinic's brand, and the treatments directory already includes sermorelin, NAD+ and PT-141 programs, so a peptide clinic can launch on the legal set now and add a substance as a catalog and protocol change rather than an engineering project. We are in private beta, quote per program, and expect the clinic to bring the medical director, the protocols and the pharmacy relationship (or choose one from the network); ask us in the demo to walk through adding a new peptide end to end, because that is the operation you will run the week FDA moves.
What it costs, DIY versus platform
One August 2026 marketing agency estimate priced a telehealth peptide clinic at $20,000 to $58,000 and 12 to 24 weeks to launch, assembling storefront, EHR, intake, billing, pharmacy and provider relationships separately; that range matches what we see in the launch budget for any DTC program built from parts, before the legal structure, LegitScript ($975 plus $2,150 a year) and the first quarter of marketing. Payment processing deserves its own line: a founder on r/PaymentProcessing in April 2026 described a two-week Stripe review for a TRT-and-peptides clinic, underwriters asking for two to three months of statements, and the reminder from another commenter that "bpc can't be prescribed." Expect underwriting to read your formulary.
On a platform the calendar collapses to weeks and the fixed cost to a monthly fee, which changes what size of clinic is viable: a 200-member peptide and hormone program at $200 a month is $40,000 of monthly revenue and, by the margin model, a real business, without national scale.
Day one, when the list moves
Prewrite three things now. A formulary change: the peptide, the pharmacy that will compound it, the protocol and the price. A patient message for members who have asked (most clinics have a waitlist by name). And a short post on your own site, published the day the list updates, because that is the week search demand spikes and the evidence-based clinics will be the ones AI assistants quote. Then confirm which list the substance landed on, confirm your pharmacy's potency testing, and add it. If your platform needs a sprint to add a product, find that out this month, not that week.
FAQ
Can telehealth prescribe peptides? Yes, for peptides that are FDA-approved drugs (semaglutide, tirzepatide, tesamorelin, bremelanotide) and for those compounded under existing rules, such as sermorelin. The twelve peptides removed from Category 2 in April 2026, including BPC-157 and TB-500, cannot be compounded or prescribed until FDA publishes an updated bulks list.
Do you need a license to sell peptides? To sell prescription peptides, yes: a licensed prescriber evaluates the patient, and a licensed pharmacy dispenses on a valid prescription. Selling injectable peptides as "research use only" to consumers is being treated by FDA and DOJ as evidence of unlawful distribution, and the largest RUO vendors shut down in 2026.
How much does it cost to start a peptide clinic? Assembling the stack yourself, one 2026 estimate is $20,000 to $58,000 and 12 to 24 weeks, plus legal structure, LegitScript and marketing. On a platform the technology becomes a monthly fee and the launch takes weeks; the legal, clinical and pharmacy costs remain.
Are peptide clinics profitable? A membership clinic at $150 to $300 a month with labs and hormone or GLP-1 programs alongside can be profitable at a few hundred members, by the same math as any cash-pay telehealth program. The risk is regulatory rather than economic: a formulary built on peptides that are not yet compoundable is not a business.
When will BPC-157 be legal to prescribe? When FDA adds it to a bulks list following the July 2026 advisory committee review. No date has been announced as of September 2026; the committee's votes were advisory, and the agency has not published an updated list.